The 2023 Pan-Mass Challenge

For more than four decades, the Pan-Mass Challenge has shown the world the true power and potential of bicycling by raising awareness of and funding for Dana-Farber Cancer Institute. The nation’s most successful athletic fundraiser and Dana-Farber’s largest single contributor, the PMC made a record-breaking $72 million gift in 2023, bringing the organization’s cumulative total to an astounding $972 million generated since 1980.

Anchoring this historic fundraising effort in 2023 was the 44th PMC ride, during which 6,156 riders from 44 states, territories, and districts and 6 countries pedaled 16 routes ranging from 25 to 211 miles across Massachusetts, or reimagined their rides in locations of their choosing. They were aided by more than 3,000 volunteers and 200 corporate sponsors whose support ensured that 100% of every rider-raised dollar goes directly to Dana-Farber. Nearly 1,000 cancer patients and survivors rode and volunteered as Living Proof of the PMC’s impact.

Critical funds were also generated by additional “spokes in the PMC wheel” including: the PMC Winter Cycle, a charitable spin event at Fenway Park in Boston; PMC Unpaved, a gravel ride taking place in the Berkshires of western Massachusetts; and PMC Kids Rides, through which children, parents, and neighbors spearheaded individual bike-a-thons in neighborhoods, at schools, or in business complexes.

Together, the committed PMC community enabled the largest individual gift in Dana-Farber’s history, accounting for more than 62% of the Jimmy Fund’s annual revenue. The present report provides an overview of the deep and broad impact of this extraordinary support, illustrating and underscoring the PMC’s paramount role in bringing cures closer by the mile.

PMC Pedal Partners – pediatric patients at the Jimmy Fund who are paired with PMC riders – provide a powerful reminder of what’s at stake in the PMC’s mission to bring cures closer. During PMC Weekend, young patients like Norma-Rose, pictured above at the annual Pedal Partner party with riders from Team Duncan, gather with their families at the Lakeville, Mass., water stop to meet and cheer on those who are riding in their honor.
I'M ALIVE
BECAUSE
OF YOU
THANK YOU RIDERS!
Founded in 1947 by Sidney Farber, MD, who pioneered modern chemotherapy and achieved the first-ever remissions in childhood leukemia, Dana-Farber Cancer Institute has been the top-ranked cancer hospital in New England by *U.S. News & World Report* for 23 consecutive years and is the only cancer center in the country ranked in the top 5 for both adult and pediatric cancer programs. As the lead cancer institution of the Dana-Farber/Harvard Cancer Center—a federally designated Comprehensive Cancer Center—Dana-Farber is at the helm of one of the world’s largest brain trusts in cancer medicine, and well-positioned to maximize the impact of the PMC’s incredible support.

PMC funding is felt throughout the Institute’s labs and clinics, allowing Dana-Farber to invest in the people and projects needed to change the course of cancer everywhere. Because of the PMC, the Institute’s trailblazing investigators can achieve pivotal breakthroughs through their pursuit of bold studies, many of which rely on philanthropy to reach “proof of concept” before other funders will invest. Dana-Farber’s dedicated caregivers can provide personalized programs that address the comprehensive needs of patients, many of which are not covered by insurance. And in a competitive hiring climate, Institute leadership can recruit and retain the best and brightest team—all because of the PMC.

“Dana-Farber is very fortunate and grateful to count on the PMC’s powerful partnership, which shapes everything we do. Because of the PMC, we are learning more about cancer, developing more treatments, and helping more patients than ever before. As our progress continues to multiply and ripple across the globe, the PMC’s life-changing impact grows with each new advance.”

Laurie H. Glimcher, MD  
President and CEO of Dana-Farber Cancer Institute
THE JIMMY FUND AT 75

In 1948, the Variety Children’s Charity of New England and the Boston Braves baseball team joined forces to help a 12-year-old cancer patient dubbed “Jimmy.” On a national radio broadcast, millions heard the boy visit with his heroes from the Braves, who stood by his hospital bed. Listeners everywhere contributed to help buy Jimmy a television so he could watch the Braves play, ultimately launching the global grassroots fundraising movement known as the Jimmy Fund.

Seventy-five years later, we honor the generosity of the millions of people worldwide who have helped the Jimmy Fund save countless lives and reduce the burden of cancer for patients and families. Each year, thousands of people raise funds for Dana-Farber by organizing, participating in, and/or supporting signature events such as the PMC, as well as hundreds of walks, runs, bake sales, and other special events in communities across the country and around the world. In 2023, the Jimmy Fund generated nearly $110 million in unrestricted funds, essential revenue that fuels innovation and experimentation, builds the foundation for further growth, and promotes health equity, along with other essential benefits.

As the Jimmy Fund’s top supporter, accounting for more than 62% of its annual revenue, the PMC plays a central role in this inspiring story and exemplifies the power of committed people united against cancer. This includes artist and multiyear PMC rider Richard Banfield, who created two cows to help CowParade New England presented by Herb Chambers raise more than $1 million for Dana-Farber in this anniversary year. One of his cows, “Commit” (pictured to the right), featured the PMC route from Sturbridge to Provincetown and was sponsored by PMC riders.

Billy Starr has led the PMC community for more than half of the Jimmy Fund’s 75-year history.
A $72 MILLION IMPACT

In 2023, committed riders, donors, sponsors, and volunteers joined together to contribute an unprecedented $72 million to Dana-Farber and the Jimmy Fund. The chart below shows how Dana-Farber allocates these funds to bring a world without cancer closer by the mile.

*This chart depicts rider-designated funds in addition to unrestricted funds directed in accordance with Institute budget priorities.*
PMC support ultimately impacts patients across the globe by driving life-changing advances in cancer research and care at Dana-Farber. Following are some of many examples of pivotal breakthroughs in which PMC funding played a role.

Driving drug development — More than half of all cancer drugs approved by the FDA in the past 5 years were developed with significant contributions from Dana-Farber investigators, thanks to PMC funding.

- **Accessible test for cancer risk** — Researchers at the Institute found a novel biomarker associated with increased risk of BRCA-related cancers. A simple blood test for this marker, which does not require genetic sequencing, could become the basis for a more accessible and affordable way to assess such risk.

- **FDA approvals of three novel therapies** — Dana-Farber studies led to FDA approvals of new treatments for metastatic HR+ and HER2-breast cancers; platinum resistant high-grade serous ovarian cancer; and relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.

- **First new treatment for glioma in decades** — A global clinical trial led by Dana-Farber researchers showed that a precision therapy called vorasidenib more than doubled progression-free survival for patients with grade 2 gliomas with IDH1 or IDH2 mutations. This is the first time a new agent has been introduced for the treatment of these tumors in more than 20 years.

- **Promising drug targets for multiple myeloma** — Institute investigators identified 116 genes as key molecular vulnerabilities for multiple myeloma, providing potential leads for the discovery of new therapies for this disease.

- **Hope for patients with advanced kidney cancer** — Dana-Farber research revealed that that a novel three-drug immunotherapy combination can significantly slow the progression of advanced kidney cancer in previously untreated patients.

- **New AI-based tool improves care** — Institute researchers created a novel tool utilizing artificial intelligence (AI) to analyze gene sequencing data and predict the primary source of a patient’s cancer, potentially improving treatment options for the 3-5% of cases in which a cancer’s origin cannot be determined.

- **Reversing treatment resistance** — A Dana-Farber-led study uncovered an epigenetic source of drug resistance in EGFR-mutant lung tumors. Researchers are currently testing whether treatment with mSWI/SNF inhibitors can reverse resistance.

- **First-in-kind national clinical trial** — Dana-Farber is leading an innovative phase 2 clinical trial in collaboration with 10 major brain tumor centers around the country aimed at finding new treatments for glioblastoma. This adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.
The PMC provides Dana-Farber researchers with the funds they need to aggressively pursue the most promising areas of scientific discovery—allowing them to say “yes” to exceptional ideas and have an immediate impact on propelling scientific breakthroughs. Grounded in the Institute’s signature synergy between the lab and the clinic, investigators are accelerating advances from bench to bedside and back again. PMC support helps spin this cycle of discovery, speeding significant progress across the spectrum of cancer detection, prevention, and treatment.

**DRUG DISCOVERY**

Strengthened by PMC support, Dana-Farber has long been a global leader in cancer drug development, creating novel agents in its world-class chemical biology program while testing promising treatments in its robust clinical trials program.

- **Chemical biology** — More than a decade ago, the Institute became one of the first cancer centers in the country to establish its own chemical biology program, which is tackling the toughest challenges in cancer drug discovery. Unique among freestanding cancer centers, Dana-Farber’s program continues to make seminal contributions in advancing targeted cancer therapies. Many of these compounds are now benefiting patients in clinical trials—for example, JQ1, a compound originally created at Dana-Farber, serves as the basis for drugs used to treat certain cancers and heart disease.

- **Clinical trials** — Institute investigators are spearheading more than 1,100 clinical trials to get new treatments from the lab to patients as quickly as possible. They also shape similar efforts at cancer centers everywhere by maximizing international knowledge-sharing opportunities via forums such as the Annual Meeting of the American Society of Clinical Oncology (ASCO)—the world’s largest clinical cancer research meeting, attracting more than 30,000 oncology professionals from across the globe. At the 2023 ASCO meeting, Dana-Farber presented findings from phase 3 trials that showed promising results for patients with brain, breast, kidney, and rectal cancers. This included a study revealing that radiation can be safely omitted in select patients with locally advanced rectal cancer, potentially reducing short- and long-term side effects while providing similar outcomes in disease-free and overall survival.

**IMMUNOTHERAPY**

From genes that regulate immune responses to foreign substances to proteins that tumor cells use to evade an immune attack, Dana-Farber has made vital discoveries about the immune system that have launched novel classes of cancer treatments. Philanthropy from the PMC has extended the Institute’s excellence in this field and enabled continuous innovation in unleashing the body’s natural defenses against cancer.

- **New combination immunotherapies for colorectal cancer and advanced kidney cancer** — Institute researchers demonstrated the promise of a combination of two next-generation immunotherapy drugs in treating patients with refractory metastatic colorectal cancer, a disease which has not previously responded well to immunotherapies. In addition, Dana-Farber investigators showed that an immunotherapy-targeted drug combination improved survival for advanced kidney cancer.

- **Uncovering resistance and enhancing responsiveness to immunotherapy** — Immunotherapy has redefined cancer treatment, but not all patients experience the same benefit when treated. According to research led at Dana-Farber, one potent factor in treatment outcome appears to be an individual’s gut microbiota—the trillions of microorganisms that live in the human intestine. Institute investigators showed that specific gut microbiota lowered the expression of two immune molecules, including one previously unknown to play a role in cancer. Conversely, using antibodies to block the activity of either molecule, or the interplay between them, enhanced response to cancer immunotherapy. These findings can inform the design of treatments that boost the efficacy of cancer immunotherapy among patients with suboptimal response, thus extending its benefits to greater numbers of people.

**PREVENTION AND EARLY DETECTION**

Building on recent advances in cancer genomics, technology, and population-based methods of prevention and early detection, Dana-Farber is improving patient outcomes by stopping cancer before it starts, or diagnosing and treating it before it progresses. With PMC support, Institute investigators are answering key questions about why cancer develops in the first place and advancing novel strategies to intervene early.

- **New tool identifies patients at high risk for blood cancer** — Clonal hematopoiesis (CH) is a recently characterized condition in which genetic mutations associated with leukemia and other blood cancers are found in the blood of individuals without cancer. By combining measures that were highly predictive of blood cancer risk in CH patients into an algorithm, Institute investigators created a tool that calculates a clonal hematopoiesis risk score (CHRS), which predicts an individual’s likelihood of developing blood cancer. The ability to now stratify CH patients according to their risk of cancer progression not only enhances early detection of these diseases, but will also help propel clinical trials for preventative interventions.
**Free online risk assessment and education** — Dana-Farber developed a free online quiz to provide an individualized assessment of a person’s risk for breast and ovarian cancers, along with action items for reducing risk, printable results to share with a doctor, and resources to help a user understand more about risk factors. The tool features inclusive language and information, offers a Spanish translation, and contains built-in explanations that help users understand the relevance of each quiz question for risk assessment and cancer prevention.

**Ultrasensitive blood test for multiple cancers** — Institute investigators led an international effort to develop a low-cost, ultrasensitive blood test that detects minute levels of a “pan-cancer” biomarker, which is highly specific to multiple common malignancies. Requiring only half a drop of blood, the test showed promise for early cancer detection and disease monitoring, and could potentially be used in conjunction with other tools for detection, risk stratification, and treatment.

**DATA SCIENCE**

Information is power, and there is no better way to use it than to save lives. PMC support is helping Dana-Farber data scientists leverage artificial intelligence, machine learning, and other advanced tools to unlock crucial insights for maximal patient benefit.

**AI tool may improve care for head and neck patients** — Researchers from Dana-Farber have found a way to use artificial intelligence to diagnose muscle wasting, called sarcopenia, in patients with head and neck cancer. Designed to indicate in real time when a patient is losing muscle mass, this new tool enables physicians to recognize this decline before it reaches a critical point. That warning sign could trigger an intervention, such as a nutritional consult, supportive medication, or physical therapy.

**Software matches patients to promising trials** — A software platform developed at the Institute has helped hundreds of Dana-Farber patients enroll in clinical trials of targeted therapies since the platform’s launch in 2017. Called MatchMiner, it uses data on the genetic features of a patient’s cancer, as well as clinical data, to identify trials at Dana-Farber for which the patient might be eligible. In assessing the program’s success, the Institute team found that trial consents were made for 20 cancer types and that 87% of patients who consented to join a clinical trial identified by MatchMiner ultimately participated in that study.

**INTERDISCIPLINARY CENTERS—DANA-FARBER’S COLLABORATIVE STRENGTH IN ACTION**

Interdisciplinary centers at the Institute bring together the brightest minds across the full spectrum of cancer medicine to address needs and maximize opportunities for advances. Leveraging resources from the PMC and other supporters, the Institute launched two exciting new centers in 2023:

The **Center for Therapeutic Discovery** provides focused funding and support to accelerate the development of novel treatments for rare or hard to treat cancers. The most promising projects receive significant resources to run key experiments and benefit from a new team of experts in drug discovery rarely found in academic medicine—ensuring that the best treatments move further along the pre-clinical pipeline and reach patients faster.

The **Centers for Early Detection and Interception (CEDI)** serve people at high risk of developing cancer and lead research in the technologies and treatments that are reshaping the field of cancer prevention. CEDI includes three centers focused on multicancer early detection, precursor conditions of hematologic cancers, and solid tumors. In Dana-Farber’s gastrointestinal cancer and gynecologic cancer disease centers, new clinics will work to identify people at increased risk for these cancers, develop screening tests, and monitor at-risk individuals for the first signs of cancer. Ultimately, similar clinics could operate in every Institute disease center.
THE DANA-FARBER CAMPAIGN: POWERED BY THE PMC

Launched in 2017, The Dana-Farber Campaign is a historic multibillion dollar fundraising effort and one of the largest-ever campaigns in the United States solely focused on cancer. As the campaign’s top single contributor, the PMC is providing the robust resources required for Dana-Farber to accelerate revolutionary science, ensure extraordinary care, and leverage exceptional expertise in defiance of cancer.

Powered by the PMC, The Dana-Farber Campaign has enabled the Institute to lead the way by:

- **Equipping our world-class faculty members, nurses, and early career investigators with critical resources** to pursue innovative ideas and bring new therapies to patients. In addition, 16 new endowed Dana-Farber Chairs have been established that will ensure long-term, durable support across disease areas.

- **Designing a new co-location model for cancer diagnostic services to improve care in the community,** which has reported a reduction in the time it takes to diagnose cancer in a community health center in Boston that cares for historically underserved populations—from a median of 32 days to 12 days.

- **Opening three new, world-class patient care facilities in the past 5 years** in Merrimack Valley, Chestnut Hill, and Foxborough—brining the total number of Dana-Faber facilities to eight providing the Institute’s signature care closer to home for more patients.

- **Doubling the size of our Cancer Care Equity Program,** allowing us to support more patients from medically underserved communities and to hire four new patient navigators in the gastrointestinal, breast, thoracic, and gynecologic cancer disease centers. Since October 2021, these navigators have helped more than 200 patients with housing, transportation, nutritional assistance, language services, mental health care, and more.

- **Launching new initiatives that leverage the unique expertise found at Dana-Farber,** such as the Center for Therapeutic Discovery, which is accelerating the development of novel treatments for the most challenging cancers; the Center for BRCA and Related Genes, one of the few dedicated BRCA centers in the world, leveraging decades of research into BRCA and BRCA-related genes to better identify risk, detect cancer at a curable stage, and design powerful new therapies; and the Young-Onset Colorectal Cancer Center, one of the first centers in the country aimed to address the increase in colon and rectal cancer patients under 50 years old.
EXTRAORDINARY CARE

In addition to revolutionizing pediatric cancer medicine with chemotherapy, Institute founder Sidney Farber, MD, broke new ground with his philosophy of “Total Patient Care.” Today, that care model, in which patient services and decisions are made in one place as a team, with the patient at the center of the discourse, remains central to Dana-Farber’s mission. Funding from the PMC supports these offerings, many of which are not covered by insurance, and all of which are essential in addressing the personalized needs of patients and families.

NURSING AND PATIENT CARE SERVICES

Strengthened by PMC funding, Dana-Farber has built a world-class nursing team that received Magnet® status—a distinction earned by only 10% of hospitals nationwide—four times since 2005 for excellence in nursing service and practice. Institute nurses are conducting original research, addressing cancer disparities, and helping patients navigate the hidden burdens of cancer, while providing the highest quality “relationship-based” care.

- **Alleviating anxiety in adult patients during infusions** – Nurse scientists in a Dana-Farber/New Hampshire Oncology-Hematology-led study showed that weighted blankets decreased anxiety in adult patients undergoing chemotherapy, with the most dramatic reductions seen at the first infusion visit. The results have prompted efforts to implement the use of weighted blankets at Dana-Farber Brigham Cancer Center at Milford Regional Medical Center and in Dana-Farber’s Jimmy Fund Clinic.

- **International nursing collaborations** – Dana-Farber collaborates with two international hospitals—Grupo Oncoclínicas in Brazil and the First Affiliated Hospital, Sun Yat-sen University in China—to deliver education, training, and strategic advisement to promote oncology services, including site visits during which Institute nurses work alongside hospital staff in their clinical settings.

PSYCHOSOCIAL AND PALLIATIVE CARE

When Dana-Farber founded the Department of Psychosocial Oncology and Palliative Care (POPC), it was one of very few departments nationally that was devoted exclusively to supportive oncology. PMC funding keeps the Institute’s team at the forefront of this important field today, by equipping them to deliver compassionate, personalized care while advancing research to improve the experience of living with cancer and to identify novel approaches to feeling better.

- **Supportive Oncology and Health Equity Initiative** – As part of Dana-Farber’s comprehensive commitment to reducing health disparities, this initiative works to incorporate supportive care into existing clinical access efforts and ensure such care is within everyone’s reach. Staff are building relationships and gathering perspectives across Boston’s communities to better understand patients’ needs, identify ways to enhance their quality of life during serious illness, and alleviate systemic barriers to getting the help they seek.

- **Novel intervention to promote resilience in young patients** – POPC investigators have developed a coaching program for patients and families with serious illness to reduce stress and build resilience. Now researchers are working to refine and expand the program to young patients and survivors, including by exploring new ways to reduce both psychological and material hardship for those experiencing poverty.

PERINI FAMILY SURVIVORS’ CENTER

People are living better and longer with cancer than ever because of the PMC. The Perini Family Survivors’ Center at Dana-Farber is advancing novel research and providing comprehensive care for this growing number of survivors through the David B. Perini, Jr. Quality of Life Clinic, which serves survivors of pediatric and adolescent cancers, and the Adult Survivorship Program.

- **First-in-kind studies uncover insights benefiting neuroblastoma survivors** – In the first national study of children and young adults who had high-risk neuroblastoma and survived at least five years, Perini program investigators revealed that survivors show increased likelihood of hearing loss and growth impairment associated with exposure to specific types of chemotherapy. These insights may help refine treatment for newly diagnosed individuals and inform long-term survivorship care. In addition, Institute researchers found that children of low socioeconomic status have lower survival compared to their counterparts, underscoring the immediate need for more interventions to alleviate socioeconomic disparities affecting neuroblastoma survival.

- **International study shows many younger women with breast cancer can safely have a baby** – A study led by Dana-Farber’s Adult Survivorship Program team revealed that for young women with hormone receptor-positive breast cancer, pausing endocrine therapy to pursue a pregnancy did not raise the short-term risk that the disease will recur. These results provide encouraging guidance to younger women with breast cancer who hope to have children, while highlighting the need to incorporate reproductive health care, treatment, and choices in working with this patient population.
NEW COLLABORATION TO TRANSFORM PATIENT CARE

Like the PMC, Dana-Farber continually strives to innovate and elevate our unrelenting efforts against cancer. That is why, with PMC support, the Institute increased its number of world-class facilities by 60%, adding three new locations that provide care closer to patients’ homes since 2018. And it is why, in September 2023, Dana-Farber announced plans for a long-term collaboration with Beth Israel Deaconess Medical Center (BIDMC) to build the region’s only independent, free-standing inpatient hospital for adult cancer patients. The proposed new state-of-the-art inpatient hospital will increase adult patient capacity and create flexibility to incorporate the latest innovations and technology in cancer care developed by the accomplished researchers and clinicians at both institutions. While it will take several years to implement the cancer collaboration and, pending regulatory approvals, construct the proposed new cancer hospital, this promising partnership presents an exciting pivot point in the trajectory of cancer medicine and holds immense potential benefit for patients.
INCLUSION, DIVERSITY, AND EQUITY

CREATING BETTER OUTCOMES FOR EVERYONE

Strengthened by PMC support, Dana-Farber’s Cancer Care Equity Program and Community Benefits team continue to expand, ensuring that growing numbers of patients benefit from the world-class cancer care they deserve.

Founded in 2012—several years before inclusion, diversity, and equity became a strong national focus—Dana-Farber’s Cancer Care Equity Program (CCEP) is reducing barriers and expanding access to exceptional cancer care through community-facing outreach programs, evidence-based education and patient navigation, and research into the causes and impacts of cancer health disparities as well as the best interventions. Following are a few of the CCEP’s signature initiatives:

- **Patient Navigation** – Community-focused patient navigators identify patients who face socioeconomic challenges and structural barriers to care, and help them obtain housing and transportation assistance, psychosocial counseling, and other resources, along with personalized support during and between appointments.

- **Clinics in the Community** – In partnership with community-based health care providers, Dana-Farber offers cancer clinics at Harvard Street Neighborhood Health Center, the Dimock Center in Roxbury, and St. Elizabeth’s Medical Center. Patients who are seen at these sites and diagnosed with cancer are referred to Dana-Farber for follow-up care.

- **Research to Eliminate Disparities** – Institute investigators are advancing an array of efforts to better understand and overcome barriers to cancer diagnosis and treatment access. For example, researchers are exploring the efficacy and feasibility of a new video-based education and patient navigation intervention within medically underrepresented patients, ultimately aiming to increase access to genomic testing.

As Chief Clinical Access and Equity Officer, Hadley Family Chair, and Faculty Director for the Cancer Care Equity Program at Dana-Farber, Christopher Lathan, MD, MS, MPH, leads the Institute’s efforts to expand its world-class care and make cancer treatment and research more inclusive and equitable.
In parallel with the CCEP, the Community Benefits team brings evidence-based tools on prevention, screening, early detection, and cancer treatment to medically underserved groups in the Greater Boston area. Outreach efforts include the following:

- **Mammography Van** – Dana-Farber’s Mammography Van, the only mobile digital mammography program in Massachusetts, features state-of-the-art imaging technology, a private reception area for check-in, and real-time image transmission to radiologists in the Institute’s breast imaging network.

- **Blum Family Resource Van** – The Blum Van team delivers cancer prevention education and skin cancer screenings to populations at a higher risk of developing this disease, such as beachgoers or those who work outdoors.
EXCEPTIONAL EXPERTISE

Dana-Farber’s global leadership in cancer medicine is rooted in its deep bench of distinguished faculty who continually surpass the highest standards of excellence. Below is a sampling of select awards earned by Dana-Farber faculty and staff, whose success is a direct reflection of the PMC’s commitment to equipping them to do their best work.

Laurie H. Glimcher, MD, president and CEO, was named to Modern Healthcare’s 50 Most Influential Clinical Executives class of 2023, which includes individuals in health care who are deemed by their peers and the senior editors of Modern Healthcare to be paving the way to better health.

William Hahn, MD, PhD, executive vice president and chief operating officer, has been named a Fellow of the National Academy of Inventors (NAI). Election as an NAI Fellow is the highest professional distinction awarded to academic inventors, recognizing those whose inventions improved quality of life, economic development, and the welfare of society.

Rachel Pozzar, PhD, RN, received 2023 Oncology Nursing Society’s Victoria Mock New Investigator Award, a prestigious honor awarded to a single candidate annually in recognition of their contributions to building a scientific foundation for oncology nursing practice.

Shail Maingi, MD, was named a 2023 Castle Connolly Top LGBTQ+ Doctor. The peer-nominated distinction is part of Castle Connolly’s Diversity, Equity, and Inclusion Initiative designed to honor top clinicians and enable patients to find clinicians with shared identities, backgrounds, and experiences.

Temidayo Fadelu, MD, MPH, received Harvard Medical School’s Young Mentor Award for his global work through Dana-Farber’s collaboration with the Butaro Cancer Center for Excellence (BCCOE), where he consults with providers, leads tumor boards in which physicians discuss patient cases, and hosts oncology education seminars. The BCCOE is a longtime partner, at which providers from the Institute’s Center for Global Cancer Medicine work with BCCOE staff and Partners In Health to reduce the global cancer burden by providing care at minimal or no cost, serving more than 1,800 patients annually.

Nikhil Munshi, MD, and Ann Partridge, MD, MPH, have been named Giants of Cancer Care by OncLive, the nation’s leading multimedia resource for oncology professionals. Out of hundreds of nominations, only 12 oncologists across the United States were named to this year’s class of inductees.

Vanessa Battista, DNP, MBA, CPNP-PC, and Kim Noonan, DNP, ANP-BC, AOCN, were selected as 2023 Fellows by the American Academy of Nursing, joining a class of distinguished inductees from across the globe who lead their fields in every area of nursing practice, research, policy, and education.
After great success with the 2022-2023 pilot cohort, the **Sponsorship Program for Underrepresented in Medicine (URiM) Early Career Faculty Program** began hosting its second group in September 2023. The program is one of many efforts underway at Dana-Farber to increase inclusion, diversity, and equity among faculty and staff, and to foster a more diverse scientific and medical community that represents all backgrounds served by the Institute.

Self-identified early career URiM faculty—defined as racial and ethnic populations that are underrepresented in the medical profession relative to their numbers in the public—are matched with Institute senior leaders who offer guidance to help advance their careers. Spearheaded by the Office for Faculty Development, Professionalism, and Inclusion at Dana-Farber, the program is distinct in that senior leaders sponsor—as opposed to mentor—early career faculty, called protégés.

While a sponsor is not always in the same discipline as their protégé, they are familiar with the latter’s field. What is most important is a sponsor’s willingness to use their position and networks to open doors. Such personal connections and professional development increase the likelihood that protégés will successfully apply for grants, obtain leadership positions, publish papers, and otherwise build productive careers—ultimately improving faculty diversity, fostering belonging and connection for people of all backgrounds, and mobilizing the best team against cancer.
“Every single one of us is affected by cancer somehow, and I believe we have to keep doing this for me and for others living with cancer.”

Mary Worthington Kachadurian
Mary was a multiyear PMC rider when she was diagnosed with follicular lymphoma while training for her ride in 2018. Six weeks after her last treatment, she rode the full PMC to Provincetown. After her cancer returned, Mary was put on a clinical trial at Dana-Farber that put her back into remission, enabling her to hit the road again in the PMC. In 2023, her 12th year as a PMC rider and 6th as a Living Proof rider, Mary surpassed $100,000 in cumulative funds raised for the Institute. This same year, her 4-year-old grandson rode in his first PMC Kids Ride, deepening the family’s involvement in fundraising for Dana-Farber’s important work—including groundbreaking clinical trials like the one that extended her life.

“I ride to give back to all those being treated at Dana-Farber and for the amazing physicians who saved my life.”

Lester Chow
Lester Chow was diagnosed with rectal cancer in 2011, when he was 54. While his journey to recovery wasn’t the easiest road, with surgery, several rounds of chemotherapy, and radiation therapy, today he is cancer-free, thanks to the care he received from his team at Dana-Farber. After his treatment, Lester got connected with the PMC, starting as a water stop volunteer in his hometown of Franklin, Mass. His nurse practitioner encouraged him to get more involved with the PMC community. For the past four years he has become a year-round volunteer, taking part in the PMC Weekend, PMC Kids Rides, PMC Winter Cycle, and PMC Unpaved. He started riding in the PMC himself in 2022.

When the PMC was founded in 1980, there were fewer than 5 million cancer survivors in the U.S. Today, that number is more than 18 million—and counting. Here are a few of them.

“Every single one of us is affected by cancer somehow, and I believe we have to keep doing this for me and for others living with cancer.”
“I ride because I want to help those affected by cancer, and because I know that, together, we can make a difference.”

Craig Bunnell, MD, MPH, MBA
Chief Medical Officer at Dana-Farber and PMC rider

Sam Gold
In late July 2022, two weeks before Sam Gold geared up for his fourth PMC, he got the unthinkable news that, at just 29 years old, he had stage II tongue cancer. He started his treatment at Dana-Farber the day after finishing the ride with his dad and brother. During treatment, Sam found support through Dana-Farber’s Young Adult Program (YAP), which provides psychosocial services and community to people age 18-39 who are facing a cancer diagnosis. He is a part of the YAP support group, has attended social gatherings, and shared his experience and challenges as part of a virtual roundtable for other patients. Sam completed radiation in November 2022, was declared cancer free as of February 2023, and completed the two-day Wellesley to Provincetown PMC ride that August.

“It’s hard to imagine a better legacy than to save a life.”
THANK YOU FOR YOUR POWERFUL PARTNERSHIP

During a long bike ride, reflection on how far one has come helps maximize motivation to go the distance. The present report represents just one of 44 years of incredible progress at Dana-Farber enabled by the PMC. Imagine how much further the Institute and the PMC can move forward together in the years ahead—as the PMC community surpasses $1 billion raised, and cycles toward the next billion.

Like the PMC, Dana-Farber has ambitious goals for the future of our shared mission, and with the PMC’s strong partnership, we aim to:

- Develop next-generation cancer drugs by identifying novel drug targets and innovative new approaches to expand treatment options and overcome treatment resistance.
- Expand access to care and improve outcomes for all patients by leading the way in cancer disparities research, helping more patients access leading-edge care and clinical trials, and building a more diverse workforce.
- Stop cancer in its tracks by developing new technologies and approaches to enhance screening, detect cancer and precancerous conditions earlier, better identify at-risk individuals, and create new precision intervention strategies.
- Harness genomic and clinical data to save more lives by expanding Dana-Farber’s expertise in AI and machine learning, and developing powerful tools that analyze complex data to expedite revolutionary advances.
- Double the impact of immunotherapies, extending the benefit of this powerful treatment option to more patients, by identifying new therapeutic targets and uncovering why immunotherapies work for some patients, but not others.

Dana-Farber’s pursuit of these and other integral efforts is grounded in the continued commitment of the entire PMC community—riders, volunteers, sponsors, and supporters. All are bringing cures closer and leading the way toward unprecedented advances against cancer. Such strides mean more patients can live better and longer than ever, and Dana-Farber remains profoundly grateful for the PMC’s integral role in this shared success.
PAN-MASS CHALLENGE BOARD OF DIRECTORS IN 2023

Mike Ascione
Managing Director, Berkshire Partners

Josh Bekenstein
Managing Director, Bain Capital; Chairman, Board of Trustees, Dana-Farber Cancer Institute

Susan Brogan
PMC Head Staff
Executive Director, Albert Research Institute for White Matter and Cognition

Lois Cornell
Executive Vice President, Massachusetts Medical Society

Mike Dee
CEO & Co-Founder, Pickleball4America

Caren Deardorf
Chief Commercial and Strategy Officer, Editas Medicine

Melany Duval
Senior Vice President and Chief Philanthropy Officer, Dana-Farber Cancer Institute and the Jimmy Fund

Alan Einhorn
Partner, Foley & Lardner LLP
Legal counsel to the board

David Fialkow
Managing Director, General Catalyst

Jonathan Gilula
EVP Business Affairs, Boston Red Sox

René Jones
Chairman and CEO, M&T Bank

Jeff Rimpas, ex-officio
PMC Head Staff
Senior Engagement Manager, ELLKAY

Bekah Salwasser
Executive Vice President of Social Impact, Boston Red Sox
Executive Director, Red Sox Foundation

Robert Smith
Managing Partner, Castanea Partners

Billy Starr
Founder and Executive Director, Pan-Mass Challenge

Setti D. Warren
Executive Director, Institute of Politics at Harvard Kennedy School

PMC PROFESSIONAL STAFF

Billy Starr
Founder / Executive Director

Jarrett Collins
Chief Executive Officer

Michele Sommer
Chief Financial Officer

Bill Alfano
Vice President of Marketing & Strategic Partnerships

Jennifer Schacter
Vice President of Technology & Digital Experience

Glynn Hawley
Director of Operations

Justine Darmanian
Director of Volunteer Operations & Kids Rides

Meredith Beaton Starr
Director of Stewardship & Liaison to DFCI

Susan Doucet
Project Manager

Deana DeSilva
Fundraising Manager

Jessica Otto Guay
Fundraising Associate

Danielle Tata
Office Administrator

Katie Iwanowicz
Marketing & Sponsorship Coordinator

PMC VOLUNTEER HEAD STAFF

Susan Brogan
Sturbridge

Mathew McGuiness
Sturbridge

Jeff Rimpas
Babson

Les Laputz
Babson

Wil Carroll
Massachusetts Maritime Academy

Anthony Polcari
Massachusetts Maritime Academy

Mike Sogard
Provincetown

Susan Pesaturo
Provincetown

Julie Paquin
Mechanical

Artie Paquin
Mechanical

Tim Gover
Public Safety & Emergency Operations

Jen Hartnett-Bullen
Weekend Operations & Logistics

Allan Eyden
Road

BJ Tynan
Medical
THE MISSION OF DANA-FARBER CANCER INSTITUTE IS TO PROVIDE EXPERT, COMPASSIONATE, AND EQUITABLE CARE TO CHILDREN AND ADULTS WITH CANCER WHILE ADVANCING THE UNDERSTANDING, DIAGNOSIS, TREATMENT, AND PREVENTION OF CANCER AND RELATED DISEASES.

THE PAN-MASS CHALLENGE (PMC) IS A FUNDRAISING BIKE-A-THON STARTED IN 1980 BY BILLY STARR TO BENEFIT DANA-FARBER CANCER INSTITUTE VIA THE JIMMY FUND. IT RAISES MORE MONEY THAN ANY OTHER SINGLE ATHLETIC FUNDRAISER IN THE COUNTRY.